Drug Profile
House-dust mite allergy immunotherapy - Lofarma
Alternative Names: Dermatophagoides injective allergoid - Lofarma; Lais® Mites Sublingual TabletsLatest Information Update: 21 Jul 2020
Price :
$50
*
At a glance
- Originator Lofarma S.p.A
- Developer Ajou University School of Medicine; Lofarma S.p.A
- Class Allergens; Allergy immunotherapies; Antiallergics
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Allergic asthma; Allergic rhinitis; Allergic rhinoconjunctivitis
Most Recent Events
- 31 Aug 2018 Launched for Allergic asthma in Germany (Sublingual) (Lofarma website, August 2018)
- 31 Aug 2018 Launched for Allergic rhinitis in Germany (Sublingual) (Lofarma website, August 2018)
- 31 Aug 2018 Launched for Allergic rhinoconjunctivitis in Germany (Sublingual) (Lofarma website, August 2018)